Harmony Ebitda from 2010 to 2024

HRMY Stock  USD 34.67  1.08  3.02%   
Harmony Biosciences EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA is likely to outpace its year average in 2024. During the period from 2010 to 2024, Harmony Biosciences EBITDA regression line of annual values had r-squared of  0.52 and arithmetic mean of  12,770,840. View All Fundamentals
 
EBITDA  
First Reported
2019-03-31
Previous Quarter
27.4 M
Current Value
72.5 M
Quarterly Volatility
33.7 M
 
Covid
Check Harmony Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Harmony Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 28.4 M, Depreciation And Amortization of 14.7 M or Interest Expense of 17.9 M, as well as many indicators such as Price To Sales Ratio of 3.14, Dividend Yield of 0.0 or PTB Ratio of 4.32. Harmony financial statements analysis is a perfect complement when working with Harmony Biosciences Valuation or Volatility modules.
  
Check out the analysis of Harmony Biosciences Correlation against competitors.

Latest Harmony Biosciences' Ebitda Growth Pattern

Below is the plot of the Ebitda of Harmony Biosciences Holdings over the last few years. It is Harmony Biosciences' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Harmony Biosciences' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Harmony Ebitda Regression Statistics

Arithmetic Mean12,770,840
Geometric Mean52,234,772
Coefficient Of Variation858.60
Mean Deviation87,060,699
Median(41,255,000)
Standard Deviation109,650,929
Sample Variance12023.3T
Range375.3M
R-Value0.72
Mean Square Error6261.4T
R-Squared0.52
Significance0
Slope17,619,815
Total Sum of Squares168326.6T

Harmony Ebitda History

2024232.6 M
2023221.5 M
2022143.6 M
2021106.4 M
20201.5 M
2019-142.7 M

About Harmony Biosciences Financial Statements

Harmony Biosciences investors use historical fundamental indicators, such as Harmony Biosciences' Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Harmony Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA221.5 M232.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Harmony Stock Analysis

When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.